Patent intelligence · EP
EP 4640274
LPAR1-INHIBITOREN
LPAR1-INHIBITOREN
Patent details — EP 4640274
- Jurisdiction
- EP
- Status
- granted
- Grant date
- Oct 29, 2025
- Expiration
- Oct 24, 2045
- Applicant
- ABBVIE INC [US]
- CPC classes
- A61K 31/ 454 A I, A61K 31/ 5355 A I, A61K/31454, A61K/314545
Quick answer
EP 4640274 (LPAR1-INHIBITOREN) is held by ABBVIE INC [US]. Status: granted. Granted Oct 29, 2025. Expires Oct 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ABBVIE INC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 454 A I, A61K 31/ 5355 A I, A61K/31454, A61K/314545, A61K/315377, A61P 19/ 00 A I
More from ABBVIE INC [US]
Related pharmaceutical patents in our USPTO index.
-
AU 2024342196
NOVEL ECTEINASCIDIN DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF
granted -
WO 2026039538
MÉTHODES DE TRAITEMENT DE TUMEURS PANCRÉATIQUES EXPRIMANT CERTAINS BIOMARQUEURS
granted -
US 20260035439
Anti-Sars-COV-2 Antibodies and Uses Thereof
granted -
EP 4670742
ANTI-CD79B-ANTIKÖRPER-WIRKSTOFFKONJUGATE
granted -
AU 2024276234
METHODS OF TREATMENT USING ANTI-C-MET ANTIBODY DRUG CONJUGATES
granted -
WO 2025230528
MÉTHODES DE TRAITEMENT DE LA SCLÉROSE LATÉRALE AMYOTROPHIQUE
granted -
US 2025333394
Tiparp Inhibitor Compounds
granted
Frequently asked questions
What is US patent 4640274?
EP 4640274 (LPAR1-INHIBITOREN) is held by ABBVIE INC [US]. Status: granted. Granted Oct 29, 2025. Expires Oct 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns EP 4640274?
ABBVIE INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does EP 4640274 expire?
Our index shows an expiration date of Oct 24, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.